Skip to main content
Home
OUR XCHANGES
BY TOPIC
ADVANCED THERAPIES
AI IN DRUG DISCOVERY
ANTIBODY THERAPEUTICS
IMMUNOTHERAPIES
MEDTECH STRATEGY
OLIGONUCLEOTIDES THERAPEUTICS
BY LOCATION
SAN FRANCISCO, USA
MUNICH, EU
PAST EVENTS
INDUSTRY EXPERTS
ADVANCED THERAPIES
AI IN DRUG DISCOVERY
ANTIBODY DRUG CONJUGATES THERAPEUTICS
ANTIBODY THERAPEUTICS
IMMUNOTHERAPIES
MEDTECH STRATEGY
OLIGONUCLEOTIDES & PEPTIDES
NEWS XCHANGE
PARTNERSHIPS
OUR PARTNERS
BECOME A PARTNER
MEDIA PARTNERS
ABOUT US
GET TO KNOW US
FAQS
MEET THE TEAM
GALLERY
CONTACT US
Home
OUR XCHANGES
BY TOPIC
ADVANCED THERAPIES
AI IN DRUG DISCOVERY
ANTIBODY THERAPEUTICS
IMMUNOTHERAPIES
MEDTECH STRATEGY
OLIGONUCLEOTIDES THERAPEUTICS
BY LOCATION
SAN FRANCISCO, USA
MUNICH, EU
PAST EVENTS
INDUSTRY EXPERTS
ADVANCED THERAPIES
AI IN DRUG DISCOVERY
ANTIBODY DRUG CONJUGATES THERAPEUTICS
ANTIBODY THERAPEUTICS
IMMUNOTHERAPIES
MEDTECH STRATEGY
OLIGONUCLEOTIDES & PEPTIDES
NEWS XCHANGE
PARTNERSHIPS
OUR PARTNERS
BECOME A PARTNER
MEDIA PARTNERS
ABOUT US
GET TO KNOW US
FAQS
MEET THE TEAM
GALLERY
CONTACT US
Sponsorship Enquiry
Register For Free
Home
OUR XCHANGES
BY TOPIC
ADVANCED THERAPIES
AI IN DRUG DISCOVERY
ANTIBODY THERAPEUTICS
IMMUNOTHERAPIES
MEDTECH STRATEGY
OLIGONUCLEOTIDES THERAPEUTICS
BY LOCATION
SAN FRANCISCO, USA
MUNICH, EU
PAST EVENTS
INDUSTRY EXPERTS
ADVANCED THERAPIES
AI IN DRUG DISCOVERY
ANTIBODY DRUG CONJUGATES THERAPEUTICS
ANTIBODY THERAPEUTICS
IMMUNOTHERAPIES
MEDTECH STRATEGY
OLIGONUCLEOTIDES & PEPTIDES
NEWS XCHANGE
PARTNERSHIPS
OUR PARTNERS
BECOME A PARTNER
MEDIA PARTNERS
ABOUT US
GET TO KNOW US
FAQS
MEET THE TEAM
GALLERY
CONTACT US
Industry Experts
Loading
Ranganath Gopalakrishnan
Director, New Modalities, Medicinal Chemistry, Early CVRM,
AstraZeneca
Sessions
02-Dec-2025
09:05 – 10:05
Advancing Oligonucleotide Therapeutics: From Molecule Design to Precision Delivery
LinkedIn
YouTube
Search
Search
Search
Username *
Password *
Login
